2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors

US7696206B2 · kind B2 · utility

Assignee

• Bayer Schering Pharma AG · DE

Inventors

• Ulrich Niewohner · Wermelskirchen, DE
• Mazen Es-Sayed · Langenfeld, DE
• Helmut Haning · Milford, US
• Thomas Schenke · Odenthal, DE
• Karl-Heinz Schlemmer · Wuppertal, DE
• Jörg Keldenich · Wuppertal, DE
• Erwin Bischoff · Wuppertal, DE
• Elisabeth Perzborn · Wuppertal, DE
• Klaus Dembowsky · Boston, US
• Peter Serno · Bensberg, DE
• Marc Nowakowski · Wuppertal, DE

Key dates

• Filing date: Sep 29, 2009
• Grant date: Apr 13, 2010
• Expiry date: Sep 29, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application claims a compound of the formula The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.